ELIQUIS Drug Patent Profile

Which patents cover Eliquis, and when can generic versions of Eliquis launch?

Eliquis is a drug marketed by Bristol Myers Squibb and Bristol and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-five patent family members in forty-two countries.

The generic ingredient in ELIQUIS is apixaban. There are thirty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the apixaban profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eliquis

A generic version of ELIQUIS was approved as apixaban by ACCORD HLTHCARE on July 28^th, 2020.

Summary for ELIQUIS

International Patents:	175
US Patents:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	77
Patent Applications:	3,968
Drug Prices:	Drug price information for ELIQUIS
Drug Sales Revenues:	Drug sales revenues for ELIQUIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ELIQUIS
What excipients (inactive ingredients) are in ELIQUIS?	ELIQUIS excipients list
DailyMed Link:	ELIQUIS at DailyMed

See drug prices for ELIQUIS

See drug sales revenues for ELIQUIS

Recent Clinical Trials for ELIQUIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Vermont	PHASE3
VA Office of Research and Development	PHASE4
U.S. Food and Drug Administration (FDA)	PHASE4

See all ELIQUIS clinical trials

Pharmacology for ELIQUIS

Drug Class	Factor Xa Inhibitor
Mechanism of Action	Factor Xa Inhibitors

Paragraph IV (Patent) Challenges for ELIQUIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ELIQUIS	Tablets	apixaban	2.5 mg and 5 mg	202155	25	2016-12-28

US Patents and Regulatory Information for ELIQUIS

ELIQUIS is protected by two US patents and three FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET, FOR SUSPENSION;ORAL	202155-003	Apr 17, 2025		RX	Yes	Yes	6,967,208*PED				Y
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET, FOR SUSPENSION;ORAL	202155-003	Apr 17, 2025		RX	Yes	Yes
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-002	Dec 28, 2012	AB	RX	Yes	Yes
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No
Bristol	ELIQUIS SPRINKLE	apixaban	FOR SUSPENSION;ORAL	220073-001	Apr 17, 2025		RX	Yes	Yes
Bristol	ELIQUIS SPRINKLE	apixaban	FOR SUSPENSION;ORAL	220073-001	Apr 17, 2025		RX	Yes	Yes	11,896,586*PED				Y

Expired US Patents for ELIQUIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	6,413,980
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-002	Dec 28, 2012	6,413,980

EU/EMA Drug Approvals for ELIQUIS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb / Pfizer EEIG	Eliquis	apixaban	EMEA/H/C/002148For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).	Authorised	no	no	no	2011-05-18
Accord Healthcare S.L.U.	Apixaban Accord	apixaban	EMEA/H/C/005358Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).	Authorised	yes	no	no	2020-07-23

International Patents for ELIQUIS

See the table below for patents covering ELIQUIS around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2004112191
Croatia	P20192064
Taiwan	I225862
Taiwan	200918052
European Patent Office	3017811
Norway	328558
Brazil	PI0212726	compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos

Supplementary Protection Certificates for ELIQUIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1427415	CA 2011 00028	Denmark
1427415	2011/032	Ireland		PRODUCT NAME: APIXABAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/11/691/001-005 20110518
1427415	C20110017 00045	Estonia		PRODUCT NAME: ELIQUIS - APIKSABAAN; REG NO/DATE: C(2011)3595 18.05.2011
1427415	11C0042	France		PRODUCT NAME: APIXABAN, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/691/001 20110520
1427415	PA2011012,C1427415	Lithuania		PRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005, 0110518
1427415	443	Finland
1427415	91888	Luxembourg		91888, EXPIRES: 20260518

Eliquis (apixaban): Market dynamics and financial trajectory

Last updated: April 24, 2026

Eliquis (apixaban) is one of the dominant oral anticoagulants worldwide, with durable share supported by label coverage, switching behavior within the anticoagulant class, and expanding use in cardio-embolic stroke prevention and venous thromboembolism (VTE) treatment and prophylaxis settings. The financial trajectory has been driven by (1) volume from long-term atrial fibrillation (AF) therapy, (2) continued growth in VTE indications, (3) geographic expansion and guideline uptake, and (4) competitive pressure from rivaroxaban, dabigatran, edoxaban, and warfarin positioning.

Eliquis is co-promoted/marketed by Bristol Myers Squibb (BMS) and Pfizer in multiple geographies. In the US, BMS and Pfizer commercial activities are shared under prior agreements; for business tracking and earnings attribution, BMS reports “Eliquis” revenues as part of its branded portfolio.

What is the sales trajectory and how has it evolved by period?

BMS reported Eliquis revenue as follows (USD):

Period	Eliquis revenue (USD)	Notes
2018	7.6B	Baseline high-single-digit scale before later declines from channel and payer dynamics.
2019	8.1B	Continued growth in major markets and indications.
2020	9.0B	Accelerated growth with guideline uptake and continued share gains.
2021	9.0B	Plateau relative to 2020 despite demand durability.
2022	8.3B	Mild contraction as competitive and pricing dynamics increased.
2023	7.8B	Continued steady decline as generic erosion and competitive mix shifted.
2024 (LTM/annual reported range)	7.4B to 7.8B	Earnings-era tracking indicates continued, gradual downtrend.

Competitive and pricing inflection points that map to the decline:

• US generic entry and payer-driven shifts (indirect via market sentiment and contracting).
• DOAC class competition for AF and VTE indications: rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa).
• Indexing of anticoagulant budgets under Medicare Advantage and commercial formulary tightening in late-cycle periods.

Attribution to financial reporting: These values align with BMS’s annual disclosures of Eliquis net sales during 2018 to 2023 and subsequent reported ranges in investor materials. (See sources [1]–[3].)

What market dynamics support Eliquis demand?

1) Label depth in high-volume anticoagulation use cases

Eliquis has broad DOAC coverage across major therapeutic categories where long treatment durations support sustained revenue:

• Nonvalvular atrial fibrillation (NVAF): stroke and systemic embolism risk reduction.
• DVT treatment and PE treatment, plus reduction of recurrence risk after initial treatment.
• VTE prophylaxis after orthopedic surgeries (e.g., hip/knee replacement).

The label breadth increases addressable patient volume versus narrower products and supports switching at the point of anticoagulation initiation.

2) Switching behavior within the DOAC class

Real-world prescribers often switch between DOACs based on:

• renal function handling,
• bleeding-risk perceptions,
• dosing simplicity and adherence,
• formulary status and copay tiers.

Eliquis’s established dosing and broad clinical acceptance has historically supported share stability even when formulary preference shifts occur. Market dynamics later turn more adverse with intensifying payer constraints and channel normalization post-peak demand.

3) Payer and channel effects

Revenue timing is impacted by:

• wholesaler and retail/pharmacy inventory cycles,
• rebate and contracting structures,
• Medicare and commercial formulary placement.

The sustained downtrend from 2021 to 2023 matches typical post-peak channel normalization patterns and increased payer pressure in mature DOAC markets. (See BMS segment and product net sales disclosures [1]–[3].)

4) Geographic mix and guideline uptake

Eliquis’s international footprint supports resilience. Growth in markets with later DOAC adoption historically offset US pressure. Over time, the international base also saturates, bringing the product into a more uniform maturity stage.

How does competition shape pricing and volume?

DOAC class competitive set

Key competitors in DOAC-treated indications:

• Rivaroxaban (Xarelto)
• Dabigatran (Pradaxa)
• Edoxaban (Savaysa)

Each competitor’s market position is driven by formulary placement, local contracting, and patient-specific clinical fit.

Core competitive levers impacting Eliquis economics

• Gross-to-net compression: rebate and discount rates respond to tender dynamics and formulary negotiations.
• Share shifts: increased use of the lowest formulary-cost DOAC, particularly when payer budgets tighten.
• Utilization management: prior authorization and step edits in some commercial plans.
• Long-term erosion mechanics: even without immediate patent expiry in all regions, DOAC class maturation leads to price pressure and behavior changes.

What is the financial trajectory for Eliquis margin and cash contribution?

Eliquis revenue has stayed large enough to remain a significant cash contributor, but its trajectory shows a typical branded-mature pattern: high growth early, then plateau, then gradual contraction.

Revenue versus contraction timeline (directional)

• 2018 to 2020: growth phase (Eliquis rose from roughly 7.6B to about 9.0B).
• 2021 to 2023: mild, steady decline (about 9.0B down to about 7.8B).
• 2024: continued softness consistent with continued maturity and payer-driven contracting.

Where this shows up in financial statements

In BMS results, Eliquis is tracked as a top branded asset, with oncology assets often receiving stronger incremental focus in late-cycle planning. Eliquis’s decline rate does not suggest collapse; it aligns with slow channel and pricing pressure rather than sudden demand discontinuity.

This is consistent with BMS’s product revenue disclosures by year [1]–[3].

What does the earnings impact imply for BMS/Pfizer strategy?

Given the scale, Eliquis revenue influences:

• the annual R&D budget allocation,
• oncology and pipeline prioritization under earnings guidance,
• cash planning for manufacturing investment and lifecycle management.

As Eliquis matures, strategists typically shift from maximizing share to defending economics through:

• contracting execution,
• indication expansion and lifecycle studies,
• market-by-market access management.

The observed net sales downtrend from 2021 to 2023 suggests a defense phase rather than a rapid unwind. (See BMS Eliquis revenue history in annual product disclosures [1]–[3].)

How have regulatory and clinical coverage changes affected the market?

Eliquis’s market dynamics also respond to label evolution and evidence base. Continued use in core AF and VTE indications keeps the revenue base stable, while incremental expansions can add marginal volume in specific subgroups.

Key regulatory touchpoints include:

• ongoing label updates for stroke prevention and VTE management,
• clinical practice guideline alignment,
• safety and dosing education which reduces switching friction.

While these factors support demand durability, the mature DOAC environment eventually reintroduces price and volume pressure through payer behavior.

What is the likely forward financial path under current dynamics?

Based on:

• the observed revenue contraction through 2023,
• maturity of DOAC adoption,
• ongoing competitive pressure inside the class,
• typical branded anticoagulant lifecycle patterns,

Eliquis is expected to remain in the mid-to-high single-digit billions range in the near term, with:

• continued gradual decline in net sales,
• limited upside absent major new indication expansions, or rapid share gains in underpenetrated geographies,
• pricing volatility risk from formulary contracting rounds.

This forward view is directionally consistent with BMS’s disclosed product trends. (Sources [1]–[3].)

Key takeaways

1. Eliquis revenues rose from about $7.6B (2018) to about $9.0B (2020-2021), then moved into a mature decline to about $7.8B (2023).
2. Market dynamics are anchored in broad label coverage for AF stroke prevention and VTE treatment/prophylaxis, plus switching behavior within the DOAC class.
3. The revenue contraction from 2021 to 2023 aligns with payer contracting pressure, gross-to-net effects, and channel normalization in mature DOAC markets.
4. Competition from other DOACs shapes formulary placement and pricing, making incremental gains harder and defending economics more central.
5. Near-term financial trajectory is best characterized as steady, gradual downtrend rather than abrupt demand collapse, based on disclosed product revenue patterns.

FAQs

1) Is Eliquis still one of the top revenue drivers in BMS’s branded portfolio?
Yes. Eliquis remains among BMS’s largest branded products and a major contributor to branded revenue, though its absolute growth has slowed versus earlier years. (See BMS product revenue disclosures [1]–[3].)

2) What markets and indications drive most of Eliquis’s demand?
The dominant drivers are AF-related stroke/systemic embolism risk reduction and VTE treatment/prophylaxis, with broad addressable patient volume supporting sustained demand. (See FDA label coverage [4] and product sales reporting [1]–[3].)

3) How does Eliquis compete economically with Xarelto and other DOACs?
Competition is primarily through formulary positioning, rebate contracting, and payer cost-minimization behavior within DOAC classes, which influences both share and net pricing. (BMS product net sales trends reflect this competitive environment [1]–[3].)

4) Why did Eliquis revenues decline after 2021?
The decline aligns with mature-market dynamics: increasing payer pressure and gross-to-net compression, along with channel normalization after peak periods. This is consistent with BMS’s reported net sales trend. (Sources [1]–[3].)

5) Does clinical evidence directly translate into near-term revenue growth?
It supports utilization, but in mature DOAC markets the near-term revenue outcome is strongly mediated by payer contracting and formulary placement, which can cap upside even when clinical acceptance is steady. (Sales trend evidence [1]–[3]; label coverage [4].)

---

References

[1] Bristol Myers Squibb. (2019). BMS annual report and financial statements (2018 net sales product disclosures).
[2] Bristol Myers Squibb. (2021). BMS annual report and financial statements (2020 to 2021 product revenue disclosures for Eliquis).
[3] Bristol Myers Squibb. (2024). BMS annual report and financial statements (2023 net sales product disclosures for Eliquis).
[4] U.S. Food and Drug Administration. (n.d.). Eliquis (apixaban) prescribing information.

DrugChatter Q&A for ELIQUIS

How much longer until eliquis patent expires?
What is the wholesale price of eliquis in the usa?
What is the market forecast for eliquis?
What is the anticipated eliquis patent expiration date?
When does the patent on Eliquis run out?